This article is a correction to:
Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
Jun Meng1†
XiaoQin Wu
Zhen Sun
RenDe Xun
MengSi Liu
Rui Hu
JianChao Huang- 1Molecular Genetics Laboratory, Suining Central Hospital, Suining, China
- 2Department of Neurosurgery, The First Affiliated Hospital, University of South China, Hengyang, China
- 3Hengyang Medical College, University of South China, Hengyang, China
By Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R and Huang J (2021). Front. Oncol. 11:698607. doi: . 10.3389/fonc.2021.698607
In the original article, there were mistakes in Table 2 as published. We collected data with reference to both the conference abstract version and the full-text published version of the TRANSCEND NHL 001 trial conducted by Abramson et al. (1, 2); in Table 2, we showed the data from the conference abstract version, which should be changed to the full-text version. The rest of the paper, including the meta-analysis and the systematic review section, was run with data from the full-text version of the TRANSCEND NHL 001 trial and is therefore unaffected. In addition, two footnotes were ignored in Table 2. The corrected Table 2 appears below.
TABLE 2
Table 2 Characteristics of included studies.
In the original article, the neurotoxicity result of tisa-cel in the Primary Mediastinal B Cell Lymphoma subgroup was incorrectly stated. A correction has been made to Results, Primary Mediastinal B Cell Lymphoma, Paragraph 1.
“A study on tisa-cel that included one patient with PMBCL with central nervous system (CNS) involvement indicated that the patient was showing ongoing response at day 90 and developed only grade 1 CRS and no ICANS”.
Secondly, a percentage was carelessly written incorrectly in the comparison of severe cytokine release syndrome between adult and pediatric patients with acute lymphoblastic leukemia. A correction has been made to Results, Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia, Paragraph 3.
“Adult patients with ALL were more likely to develop grade ≥3 CRS than pediatric patients (71 vs 47%, respectively)”.
In addition, we carelessly wrote “tisa-cel” instead of “liso-cel” and used a wrong percentage in one place. A correction has been made to Discussion, Paragraph 5.
“In the TRANSCEND NHL 001 trial, 7% of patients received non-conforming products, two patients experienced manufacturing failure of liso-cel, and 10% of patients died before receiving liso-cel.”
In the original article, there was a mistake in the legend for Figure 8 as published. “tisa-cel” was carelessly written as “axi-cel”. The correct legend appears below.
FIGURE 8
Figure 8 The forest plots of pooled results in patients with acute lymphoblastic leukemia. (A) The forest plot of complete response rate of tisa-cel. (B) The forest plot of severe cytokine release syndrome rate of tisa-cel. (C) The forest plot of severe immune effector cell-associated neurotoxicity syndrome rate of tisa -cel.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Pivotal Safety and Efficacy Results From Transcend NHL 001, A Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood (2019) 134(Supplement_1):241. doi: 10.1182/blood-2019-127508
Keywords: chimeric antigen receptor T-cell product, CAR-T cell therapy, immunotherapy, lymphoma, leukemia, hematologic malignancy, efficacy, safety
Citation: Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R and Huang J (2021) Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. Front. Oncol. 11:768128. doi: 10.3389/fonc.2021.768128
Received: 31 August 2021; Accepted: 08 September 2021;
Published: 07 October 2021.
Edited and reviewed by:
Sairah Ahmed, University of Texas MD Anderson Cancer Center, United StatesCopyright © 2021 Meng, Wu, Sun, Xun, Liu, Hu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: JianChao Huang, bGl0ZXJhdHVzeWFueXVuQDE2My5jb20=
†These authors have contributed equally to this work and share first authorship